资讯

Sellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trial
SELLAS Life Sciences (SLS) announced Cohort 3 data from the ongoing Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in ...
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of ...
Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or ...